

June 21, 2017

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001.

Io,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

**Sub:- Glenmark Pharmaceuticals Licenses Small Molecule Oncology Compound from
APC Therapeutics to Expand Immuno-Oncology Portfolio**

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Ltd.



Harish Küber
Company Secretary & Compliance Officer

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

Press Release

For Immediate Release

Glenmark Pharmaceuticals Licenses Small Molecule Oncology Compound from APC Therapeutics to Expand Immuno-Oncology Portfolio

MUMBAI, India; June 21, 2017: Glenmark Pharmaceuticals, a global pharmaceutical company, announced today it entered into a licensing agreement with Boston-based APC Therapeutics Inc., a biopharmaceutical company focused on building a portfolio of best-in-class immuno-oncology (IO) therapies, for exclusive rights to a small molecule, oncology compound based on Antigen Presenting Cell (APC) biology. The compound has the potential to be used as a monotherapy or in combination with approved therapies to address unmet needs in cancer treatment.

“This asset adds to our robust biologics pipeline of targeted IO therapies,” said Kurt Stoeckli, President and Chief Scientific Officer at Glenmark Pharmaceuticals. “The mechanism of action of APC biology is very intriguing and has the potential to be transformative in cancer treatment by triggering powerful immunologic responses to tumors that may lead to deeper and more durable responses to treatment.”

Under the terms of the agreement, Glenmark will license the product from APC Therapeutics, and manage all clinical development including regulatory filings and commercialization worldwide. APC Therapeutics will receive development milestones and sales royalty payments.

“Glenmark is an ideal partner to advance such an important scientific breakthrough treatment to patients with cancer,” said Vinod Patel and Venkateshwar Reddy, the co-founders of APC Therapeutics. “This partnership is strategically significant for APC Therapeutics as it validates and advances our commitment to bring the right immunotherapies to the right patient populations.”

The global oncology market is growing exponentially and projected to exceed \$150 billion by 2020, according to figures from IMS Health. Driving this growth is the transition from short-term cytotoxic treatments towards precision medicines, most notably IO agents providing substantial increase in long-term survival. Because of these improvements, IO is one of the most promising and fastest growing areas of cancer treatment and research.

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd. (GPL) is a global innovative pharmaceutical company with operations in more than 50 countries. The company has improved the lives of millions of patients by offering safe, affordable medications for nearly 40 years. Glenmark has a diverse pipeline with several compounds in various stages of clinical development, primarily focused in the areas of oncology, respiratory, and dermatology and includes three bispecific monoclonal antibodies (bsABs) and an antibody-based agonist targeting OX40R. The immuno-oncology pipeline currently includes four candidates being studied in a wide-range of tumor types. For more information, visit www.glenmarkpharma.com.

About APC Therapeutics

APC Therapeutics is a privately held biopharmaceutical company building a unique immuno-oncology portfolio with a focus on the development of novel small molecule therapies. The approach involves antigen-presenting cell mechanisms of action and a patient stratification to match patients most likely to respond.

For further information, please contact:

Ramkumar Uppara/Shibani Shah

Glenmark, Mumbai, India

Tel: [+91 22] 4018 9984/9348

Email: corpcomm@glenmarkpharma.com